DGAP-Adhoc

U.S. Centers for Medicare & Medicaid Services publish negative NCD for Epi proColon

DGAP-Ad-hoc: Epigenomics AG / Key word(s): Miscellaneous U.S. Centers for Medicare & Medicaid Services publish negative NCD for Epi proColon 20-Jan-2021 / 00:02 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. U.S. Centers for Medicare & Medicaid Services publish negative NCD for Epi proColon

Berlin, January 19, 2021 - Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the "Company") announces that the U.S. Centers for Medicare & Medicaid Services (CMS) have issued a negative reimbursement decision in connection with the National Coverage Determination (NCD) of Epi proColon, Epigenomics' blood test for colorectal cancer screening. The Company is currently evaluating options for an appeal, litigation and/or other alternatives to achieve Medicare coverage.
 

Contact:
Company
Epigenomics AG, Geneststrasse 5, 10829 Berlin
Tel [phone], Fax [phone], e-mail: [e-mail]

Investor Relations
IR.on AG, Frederic Hilke, Tel [phone], e-mail: [e-mail]

Forward-Looking Statements

This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any expected results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

---

20-Jan-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

---

Language:	English
Company:	Epigenomics AG
	Geneststraße 5
	10829 Berlin
	Germany
Phone:	[phone]
Fax:	[phone]
E-mail:	[e-mail]
Internet:	www.epigenomics.com
ISIN:	DE000A3H2184
WKN:	A3H218
Listed:	Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID:	1161805

End of Announcement	DGAP News Service

1161805  20-Jan-2021 CET/CEST